This article was originally published in The Rose Sheet
Executive SummarySales of firm's Bull Frog sun care line soared 92% in the third quarter, driven by "increased distribution and display programs and reduced returns," Chattem reports Sept. 17. Selsun blue sales were up 6%, and domestic factory shipments have grown from approximately $20 mil. in 2001 to a projected $34 mil. this year, Chattem states. Bull Frog, Selsun blue, Gold Bond, Icy Hot, Aspercreme and Pamprin led a 12% sales increase to $66.1 mil. in the quarter, which was offset by a 41% decline in Dexatrim sales. Operating income excluding charges related to settlement of litigation concerning Dexatrim with phenylpropanolamine (PPA) was $16.8 mil., up 6%, and net income excluding litigation settlement charges advanced 36% to $9.3 mil. Firm also announces it will introduce a number of new products under Bull Frog, pHisoderm and Gold Bond brands...
You may also be interested in...
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.